ليتروزول تيڤع

Country: Israel

Language: Arabic

Source: Ministry of Health

Buy It Now

Active ingredient:

LETROZOLE 2.5 MG

Available from:

TEVA PHARMACEUTICAL INDUST.LTD

ATC code:

L02BG04

Pharmaceutical form:

TABLETS

Administration route:

PER OS

Manufactured by:

TEVA PHARMACEUTICAL INDUSTRIES LTD

Therapeutic group:

LETROZOLE

Therapeutic indications:

Letrozole teva tablets is indicated for first-line treatment in postmenopausal women with hormone receptor positive or in whom hormone receptor status cannot be determined, locally advanced or metastatic breast cancer: Letrozole teva is also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy. Extended adjuvant treatment of early breast cancer in post menopausal women who have received prior standard adjuvant tamoxifen therapy. Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.

Authorization date:

2010-01-01

Search alerts related to this product